Vivek Subbiah/LinkedIn
Jun 14, 2025, 03:06
Vivek Subbiah Shared JCO Paper on Molecular Profiling as Standard of Care in Rare Cancers
Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a post on LinkedIn:
“Hot off the press!
Huge congratulations to JCO Oncology Practice on their 20th anniversary a remarkable milestone in advancing oncology care!
With American Society of Clinical Oncology (ASCO) 2025 annual meeting now in the rearview and momentum building toward EHA 2025, this couldn’t be better timed around the 20th anniversary of ASCO JOP journal.
Delighted to share our Policy and Practice paper: “Imperative of Comprehensive Molecular Profiling as Standard of Care for Patients With Rare Cancers”.
This paper underscores the critical need for precision-driven diagnostics to reshape how we approach rare cancers-ensuring EVERY patient gets the targeted care they deserve!”
Title: Imperative of Comprehensive Molecular Profiling as Standard of Care for Patients With Rare Cancers
Journal: JCO
Authors: Vivek Subbiah, Razelle Kurzrock
More posts featuring Vivek Subbiah on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023